Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients.

Crombag LMMJ, Szlubowski A, Stigt JA, Schuurbiers O, Korevaar DA, Bonta PI, Annema JT.

Lung Cancer. 2017 Jun;108:38-44. doi: 10.1016/j.lungcan.2017.02.011. Epub 2017 Feb 20.

PMID:
28625645
2.

Spondylodiskitis after Dilatation of Esophageal Radiation Stenosis: A Suspect for Metastasis.

Stigt JA, Vossenkaul R, de Vos Tot Nederveen Cappel WH.

J Thorac Oncol. 2017 Jun;12(6):1021-1022. doi: 10.1016/j.jtho.2017.03.016. Epub 2017 Mar 27. No abstract available.

PMID:
28359869
3.

Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

Hendriks LE, Brouns AJ, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JS, De Ruysscher DK, Van den Heuvel MM, Dingemans AC.

Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008. Epub 2016 Sep 9.

4.

Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.

Koopman D, van Dalen JA, Stigt JA, Slump CH, Knollema S, Jager PL.

Ann Nucl Med. 2016 Feb;30(2):145-52. doi: 10.1007/s12149-015-1041-z. Epub 2015 Dec 7.

5.

Ultrasound-Guided Tissue Core Biopsies in Supraclavicular Lymph Nodes in Patients with Suspected Thoracic Malignancies.

Stigt JA, Boers JE, Boomsma MF.

Respiration. 2015;90(5):412-5. doi: 10.1159/000441301. Epub 2015 Oct 21.

PMID:
26484528
6.

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.

Mellema WW, Masen-Poos L, Smit EF, Hendriks LE, Aerts JG, Termeer A, Goosens MJ, Smit HJ, van den Heuvel MM, van der Wekken AJ, Herder GJ, Krouwels FH, Stigt JA, van den Borne BE, Haitjema TJ, Staal-Van den Brekel AJ, van Heemst RC, Pouw E, Dingemans AM.

Lung Cancer. 2015 Nov;90(2):249-54. doi: 10.1016/j.lungcan.2015.09.012. Epub 2015 Sep 15.

PMID:
26415993
7.

The Identification of Stenotrophomonas maltophilia Contamination in Ultrasound Endoscopes and Reproduction of Decontamination Failure by Deliberate Soiling Tests.

Stigt JA, Wolfhagen MJ, Smulders P, Lammers V.

Respiration. 2015;89(6):565-71. doi: 10.1159/000381725. Epub 2015 Apr 30.

PMID:
25925975
8.

Percutaneous ultrasonography as imaging modality and sampling guide for pulmonologists.

Stigt JA, Groen HJ.

Respiration. 2014;87(6):441-51. doi: 10.1159/000362930. Epub 2014 May 13. Review.

PMID:
24853327
9.

Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUS-derived cytologic samples of adenocarcinomas of the lung.

Stigt JA, 'tHart NA, Knol AJ, Uil SM, Groen HJ.

J Thorac Oncol. 2013 Aug;8(8):1012-8. doi: 10.1097/JTO.0b013e31829ce93e.

10.

FDG uptake in the chest wall of a patient with small-cell lung cancer.

Stigt JA, Boomsma MF, van Bemmel BC.

J Thorac Oncol. 2013 Jun;8(6):806-7. doi: 10.1097/JTO.0b013e318287c544. No abstract available.

11.

Esophageal fistula after EUS-FNA in a patient treated with bevacizumab for non-small-cell lung cancer.

Stigt JA, Boomsma MF, de Vos tot Nederveen Cappel WH.

J Thorac Oncol. 2013 Mar;8(3):e25-6. doi: 10.1097/JTO.0b013e318282e029. No abstract available.

12.

A randomized controlled trial of postthoracotomy pulmonary rehabilitation in patients with resectable lung cancer.

Stigt JA, Uil SM, van Riesen SJ, Simons FJ, Denekamp M, Shahin GM, Groen HJ.

J Thorac Oncol. 2013 Feb;8(2):214-21. doi: 10.1097/JTO.0b013e318279d52a.

13.

Diagnosing infectious spondylodiscitis with endoscopic ultrasound.

Stigt JA, Wolfhagen MJ, Boomsma MF, Mostert AK, Groen HJ.

J Bronchology Interv Pulmonol. 2012 Jan;19(1):82-4. doi: 10.1097/LBR.0b013e3182446924. No abstract available.

PMID:
23207274
14.

Analysis of "dry" mesothelioma with ultrasound guided biopsies.

Stigt JA, Boers JE, Groen HJ.

Lung Cancer. 2012 Dec;78(3):229-33. doi: 10.1016/j.lungcan.2012.09.004. Epub 2012 Sep 26.

PMID:
23021044
15.

A novel EGFR mutation in exon 19 showed stable disease after TKI treatment.

van der Wekken AJ, Stigt JA, A't Hart N.

J Thorac Oncol. 2012 Aug;7(8):e8. doi: 10.1097/JTO.0b013e31825ccae8. No abstract available.

16.

A diagnostic program for patients suspected of having lung cancer.

Stigt JA, Uil SM, Oostdijk AH, Boers JE, van den Berg JW, Groen HJ.

Clin Lung Cancer. 2012 Nov;13(6):475-81. doi: 10.1016/j.cllc.2012.03.001. Epub 2012 Apr 11.

PMID:
22498114
17.

Percutaneous ultrasound-guided biopsies in the evaluation of thoracic tumours after PET-CT: a prospective diagnostic study.

Stigt JA, Oostdijk AH, Boers JE, van den Berg JW, Groen HJ.

Respiration. 2012;83(1):45-52. doi: 10.1159/000330018. Epub 2011 Sep 16.

PMID:
21934274
18.

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P.

Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16.

PMID:
21684151
19.

Mediastinal incidentalomas.

Stigt JA, Boers JE, Oostdijk AH, van den Berg JW, Groen HJ.

J Thorac Oncol. 2011 Aug;6(8):1345-9. doi: 10.1097/JTO.0b013e31821d41c8.

20.

Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study.

Maas KW, El Sharouni SY, Phernambucq EC, Stigt JA, Groen HJ, Herder GJ, Van Den Borne BE, Senan S, Paul MA, Smit EF, Schramel FM.

Anticancer Res. 2010 Oct;30(10):4237-43.

PMID:
21036747

Supplemental Content

Loading ...
Support Center